99mTc-MAA overestimates the absorbed dose to the lungs in radioembolization: a quantitative evaluation in patients treated with 166Ho-microspheres

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 10, 2014, Pages 1965-1975

  Elschot, Mattijs ^a   Nijsen, Johannes F W ^a   Lam, Marnix G E H ^a   Smits, Maarten L J ^a   Prince, Jip F ^a   Viergever, Max A ^a,b   van den Bosch, Maurice A A J ^a   Zonnenberg, Bernard A ^a   de Jong, Hugo W A M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Holmium 166; Lung shunt fraction; Radiation pneumonitis; Radioembolization; SPECT CT

Indexed keywords

HOLMIUM; MACROSALB TC 99M; MICROSPHERE; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT;

ADULT; ADVERSE EFFECTS; AGED; ARTIFICIAL EMBOLISM; CLINICAL TRIAL; FEMALE; HUMAN; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROCEDURES; PROSPECTIVE STUDY; RADIATION DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; EMBOLIZATION, THERAPEUTIC; FEMALE; HOLMIUM; HUMANS; LUNG NEOPLASMS; MALE; MICROSPHERES; MIDDLE AGED; PROSPECTIVE STUDIES; RADIOISOTOPES; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; TECHNETIUM TC 99M AGGREGATED ALBUMIN; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84919344616     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-014-2784-9     Document Type: Article

References (42)

1. Coldwell D, Sangro B, Salem R, Wasan H, Kennedy A. Radioembolization in the treatment of unresectable liver tumors: experience across a range of primary cancers. Am J Clin Oncol. 2012;35:167–77.
2. Vente MA, Wondergem M, van der Tweel I, et al. Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. Eur Radiol. 2009;19:951–9.
3. Riaz A, Lewandowski RJ, Kulik LM, Mulcahy MF, Sato KT, Ryu RK, et al. Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review. J Vasc Intervent Radiol. 2009;20:1121–30.
4. Sato K, Lewandowski RJ, Bui JT, Omary R, Hunter RD, Kulik L, et al. Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol. 2006;29:522–9.
5. Lam M, Louie J, Iagaru A, Goris M, Sze D. Safety of repeated yttrium-90 radioembolization. Cardiovasc Intervent Radiol. 2013;36:1320–8.
6. Sangro B, Gil-Alzugaray B, Rodriguez J, Sola I, Martinez-Cuesta A, Viudez A, et al. Liver disease induced by radioembolization of liver tumors. Cancer. 2008;112:1538–46.
7. Kennedy AS, McNeillie P, Dezarn WA, Nutting C, Sangro B, Wertman D, et al. Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys. 2009;74:1494–500.
8. Lam MG, Banerjee S, Louie JD, Abdelmaksoud MH, Iagaru AH, Ennen RE, et al. Root cause analysis of gastroduodenal ulceration after yttrium-90 radioembolization. Cardiovasc Intervent Radiol. 2013;36:1536–47.
9. Murthy R, Brown DB, Salem R, Meranze SG, Coldwell DM, Krishnan S, et al. Gastrointestinal complications associated with hepatic arterial yttrium-90 microsphere therapy. J Vasc Intervent Radiol. 2007;18:553–62.
10. Leung TW, Lau WY, Ho SK, Ward SC, Chow JH, Chan MS, et al. Radiation pneumonitis after selective internal radiation treatment with intraarterial (90)yttrium-microspheres for inoperable hepatic-tumors. Int J Radiat Oncol Biol Phys. 1995;33:919–24.
11. Wright CL, Werner JD, Tran JM, Gates VL, Rikabi AA, Shah MH, et al. Radiation pneumonitis following yttrium-90 radioembolization: case report and literature review. J Vasc Intervent Radiol. 2012;23:669–74.
12. Dancey JE, Shepherd FA, Paul K, Sniderman KW, Houle S, Gabrys J, et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic Y-90-microspheres. J Nucl Med. 2000;41:1673–81.
13. Slauson DO, Hahn FF, Benjamin SA, Chiffelle TL, Jones RK. Inflammatory sequences in acute pulmonary radiation-injury. Am J Pathol. 1976;82:549–72.
14. Yorke ED, Jackson A, Rosenzweig KE, Braban L, Leibel SA, Ling CC. Correlation of dosimetric factors and radiation pneumonitis for nonsmall-cell lung cancer patients in a recently completed dose escalation study. Int J Radiat Oncol Biol Phys. 2005;63:672–82.
15. Ho S, Lau WY, Leung TW, Chan M, Johnson PJ, Li AK. Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med. 1997;24:293–8.
16. Kennedy AS, Nag S, Salem R, Murthy R, McEwan AJ, Nutting C, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys. 2007;68:13–23.
17. Ho S, Lau WY, Leung TW, Chan M, Ngar YK, Johnson PJ, et al. Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours. Eur J Nucl Med. 1996;23:947–52.
18. Salem R, Parikh P, Atassi B, Lewandowski RJ, Ryu RK, Sato KT, et al. Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution. Am J Clin Oncol. 2008;31:431–8.
19. Yu N, Srinivas SM, DiFilippo FP, Shrikanthan S, Levitin A, McLennan G, et al. Lung dose calculation with SPECT/CT for 90yttrium radioembolization of liver cancer. Int J Radiat Oncol Biol Phys. 2013;85:834–9.
20. Elschot M, Vermolen BJ, Lam MG, de Keizer B, van den Bosch MA, de Jong HW. Quantitative comparison of PET and bremsstrahlung SPECT for imaging the in vivo yttrium-90 microsphere distribution after liver radioembolization. PLoS One. 2013;8:e55742.
21. Smits ML, Nijsen JF, van den Bosch MA, Lam MG, Vente MA, Mali WP, et al. Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study. Lancet Oncol. 2012;13:1025–34.
22. Elschot M, Smits ML, Nijsen JF, Lam MG, Zonnenberg BA, van den Bosch MA, et al. Quantitative Monte Carlo-based holmium-166 SPECT reconstruction. Med Phys. 2013;40:112502.
23. Smits ML, Nijsen JF, van den Bosch MA, Lam MG, Vente MA, Huijbregts JE, et al. Holmium-166 radioembolization for the treatment of patients with liver metastases: design of the phase I HEPAR trial. J Exp Clin Cancer Res. 2010;29:70.
24. Salem R, Lewandowski RJ, Sato KT, Atassi B, Ryu RK, Ibrahim S, et al. Technical aspects of radioembolization with 90Y microspheres. Tech Vasc Intervent Radiol. 2007;10:12–29.
25. Xiao JB, de Wit TC, Staelens SG, Beekman FJ. Evaluation of 3D Monte Carlo-based scatter correction for Tc-99m cardiac perfusion SPECT. J Nucl Med. 2006;47:1662–69.
26. de Wit TC, Xiao J, Nijsen JF, van het Schip FD, Staelens SG, van Rijk PP, et al. Hybrid scatter correction applied to quantitative holmium-166 SPECT. Phys Med Biol. 2006;51:4773–87.
27. Bol GH, Kotte AN, van der Heide UA, Lagendijk JJ. Simultaneous multi-modality ROI delineation in clinical practice. Comput Methods Prog Biomed. 2009;96:133–40.
28. de Jong HW, Beekman FJ. Rapid simulation of downscatter in non-uniform media. Phys Med Biol. 2001;46:621–35.
29. de Jong HWAM, Wang WT, Frey EC, Viergever MA, Beekman FJ. Efficient simulation of SPECT down-scatter including photon interactions with crystal and lead. Med Phys. 2002;29:550–60.
30. van Dyk J, Keane TJ, Rider WD. Lung density as measured by computerized-tomography – implications for radiotherapy. Int J Radiat Oncol Biol Phys. 1982;8:1363–72.
31. Vente MA, Nijsen JF, de Wit TC, Seppenwoolde JH, Krijger GC, Seevinck PR, et al. Clinical effects of transcatheter hepatic arterial embolization with holmium-166 poly(L-lactic acid) microspheres in healthy pigs. Eur J Nucl Med Mol Imaging. 2008;35:1259–71.
32. Sabet A, Ahmadzadehfar H, Muckle M, Haslerud T, Wilhelm K, Biersack HJ, et al. Significance of oral administration of sodium perchlorate in planning liver-directed radioembolization. J Nucl Med. 2011;52:1063–7.
33. Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF, et al. MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med. 1999;40:37S–61S.
34. Bult W, Vente MAD, Zonnenberg BA, van het Schip AD, Nijsen JFW. Microsphere, radioembolization of liver malignancies: current developments. Q J Nucl Med Mol Imaging. 2009;53:325–35.
35. Taplin GV, MacDonald NS. Radiochemistry of macroaggregated albumin and newer lung scanning agents. Semin Nucl Med. 1971;1:132–52.
36. Zolle I, Bremer PO, Janoki G. Monographs of 99mTc pharmaceuticals. In: Zolle I, ed. Technetium-99m pharmaceuticals. Berlin: Springer; 2007. p. 173–337.
37. Zielhuis SW, Nijsen JF, De RR. Production of GMP-grade radioactive holmium loaded poly(L-lactic acid) microspheres for clinical application. Int J Pharm. 2006;311:69–74.
38. Pasciak AS, Erwin WD. Effect of voxel size and computation method on Tc-99m MAA SPECT/CT-based dose estimation for Y-90 microsphere therapy. IEEE Trans Med Imaging. 2009;28:1754–8.
39. Elschot M, Nijsen JF, Dam AJ, de Jong HW. Quantitative evaluation of scintillation camera imaging characteristics of isotopes used in liver radioembolization. PLoS One. 2011;6:e26174.
40. Willowson K, Bailey DL, Baldock C. Quantifying lung shunting during planning for radio-embolization. Phys Med Biol. 2011;56:N145–52.
41. Ahmadzadehfar H, Sabet A, Biermann K, Muckle M, Brockmann H, Kuhl C, et al. The significance of (99m)Tc-MAA SPECT/CT liver perfusion imaging in treatment planning for (90)Y-microsphere selective internal radiation treatment. J Nucl Med. 2010;51:1206–12.
42. Lau WY, Kennedy AS, Kim YH, Lai HK, Lee RC, Leung TW, et al. Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres. Int J Radiat Oncol Biol Phys. 2012;82:401–7.